Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Operating Income (2016 - 2025)

Altimmune (ALT) has disclosed Operating Income for 16 consecutive years, with -$20.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Income rose 15.78% to -$20.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$90.5 million, a 19.18% increase, with the full-year FY2024 number at -$103.2 million, down 7.55% from a year prior.
  • Operating Income was -$20.9 million for Q3 2025 at Altimmune, up from -$22.9 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$14.9 million in Q1 2021 to a low of -$33.6 million in Q4 2023.
  • A 5-year average of -$23.7 million and a median of -$23.1 million in 2022 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: crashed 123.12% in 2021, then grew 26.04% in 2024.
  • Altimmune's Operating Income stood at -$24.0 million in 2021, then rose by 3.71% to -$23.1 million in 2022, then crashed by 45.59% to -$33.6 million in 2023, then rose by 26.04% to -$24.9 million in 2024, then rose by 16.11% to -$20.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Operating Income are -$20.9 million (Q3 2025), -$22.9 million (Q2 2025), and -$21.8 million (Q1 2025).